psilocybin therapy v. escitalopram treatment for depression
The latest paper on psilocybin therapy is titled "Personality change in a trial of psilocybin therapy v. escitalopram treatment for depression." It was published on June 2, 2023.
The study was a phase 2, double-blind, randomized, active comparator controlled trial involving patients with moderate-to-severe major depressive disorder. The researchers compared the effects of psilocybin with escitalopram over a core 6-week trial period. They measured Five-Factor model personality domains, Big Five Aspect Scale Openness aspects, Absorption, and Impulsivity at Baseline, Week 6, and Month 6 follow-up.
The results showed that psilocybin therapy was associated with decreases in neuroticism, introversion, disagreeableness, impulsivity, and increases in absorption, conscientiousness, and openness at week 6. At month 6, neuroticism remained decreased and agreeableness remained increased. Escitalopram was also associated with similar changes in personality traits.
The conclusion of the study was that personality changes across both conditions were in a direction consistent with improved mental health. However, there were no compelling between-condition differences warranting conclusions regarding a selective action of psilocybin therapy on specific personality traits.
You can find more details about this study on PubMed with the PMID- 37264814.
This link can't be embedded.
Want to print your doc? This is not the way.
Try clicking the ⋯ next to your doc name or using a keyboard shortcut (
